WDR3 undergoes phase separation to mediate the therapeutic mechanism of Nilotinib against osteosarcoma

Background Osteosarcoma is highly invasive with a poor prognosis. The phenomenon of liquid-liquid phase separation (LLPS) can promote the formation of biomolecules and participate in the tumor regulation mechanism. Therefore, mining prognostic markers related to LLPS could allow patients to benefit from targeted therapies. Method Microarray analysis was performed to identify LLPS-related biomarkers, followed by validation via molecular docking analysis. Functions of key genes were investigated in U2-OS cells and xenograft mice. LLPS of the key gene were observed by the droplet formation assay and fluorescence recovery after photobleaching. The intrinsically disordered region (IDR) was predicted and mutated to disrupt LLPS, which was rescued by the fusion of hnRNAP1 IDR. Therapeutic mechanism of Nilotinib mediated by LLPS was explored in vitro and in vivo . Results Five LLPS-related biomarkers were screened by bioinformatics analyses to predict the osteosarcoma prognosis. These prognostic signatures were significantly associated with immune cell infiltration, tumor immune escape and drug sensitivity. Among them, WDR3 was a prognostic risk factor for osteosarcoma and stably bound to Nilotinib in molecular docking models. In transfected U2-OS cells and xenograft mice, downregulation of WDR3 significantly inhibited malignant progression of osteosarcoma. More importantly, WDR3 could form droplets in U2-OS cells and restore the fluorescence intensity of WDR3 condensates with liquid-like behavior after photobleaching. The mutation in IDR could disrupt the phase separation ability of WDR3, whereas the fusion of hnRNAP1 IDR rescued the phase separation abnormality caused by WDR3 mutation. Moreover, treatment with Nilotinib improved the progression of osteosarcoma in vivo and in vitro , while inhibiting the production of WDR3 phase separated condensates. Conclusion WDR3 phase separation involves in the therapeutic mechanism of Nilotinib against osteosarcoma, and thus may serve as a potent biomarker to ameliorate adverse events after osteosarcoma treatment.